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Abstract
Background: Tanzania, like other low-income countries, has an increasing cancer burden that remains
underestimated. Infection-associated malignancies, particularly HIV-infection, represent a great proportion of cancer
burden in Tanzania and throughout Africa. Availability of HIV treatment and improved survival of HIV patients are
suggested factors related to increasing prevalence of non-AIDS-defining cancers (NADCs). This study examined
patterns of NADCs and proportions of HIV-positivity at the Ocean Road Cancer Institute (ORCI).
Methods: We reviewed logbooks of all ORCI patients diagnosed and/or treated for lung, liver, and head and neck
cancers during 2002–2014. The number of total cancers diagnosed at ORCI during this period was used to calculate
proportions of NADCs. We abstracted medical records to obtain demographic and clinical profiles and HIV status
information for 1127 patients diagnosed or treated during 2010–2014. Trends in numbers and proportions of
NADCs were analyzed using Joinpoint regression. Characteristics of NADC patients were analyzed using multinomial
logistic regression.
Results: NADCs diagnosed at ORCI increased by 33.8% from 2002 to 2014 while the proportion of NADCs relative to
all cancers significantly decreased from 6.8% in 2002 to 5.6% in 2014 (APC = -2.74%). Numbers and proportions of lung
and liver cancers increased compared to all cancer diagnoses from 2002 to 2014. The number of head and neck
cancers increased while decreasing proportionally compared to all cancer diagnoses from 2002 to 2014. Among
patients with pathologically confirmed NADCs between 2010 and 2014, HIV prevalence showed a non-statistically
significant decrease from 8.1 to 7.1% (APC = -3.77%).
Conclusions: Absolute numbers of lung, liver, and head and neck cancers increased at ORCI by 1/3 since 2002.
Improving survivorship of HIV patients and varying immunodeficiency status may have contributed to the increasing
number of NADCs. Total cancer diagnoses nearly doubled during this period, leading to a smaller relative proportion of
NADCs diagnosed in 2014 compared to 2002. Late- stage diagnosis and short survival of NADCs included this study
may explain possible underestimation and smaller increase in proportion of these particular NADCs compared to other
NADCs studied in Tanzania. The slight decrease in proportion of HIV-positive NADC patients during 2010–2014 may
suggest increasing patient longevity and more effective HIV management in Tanzania.
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Background
In 2013, 14.9 million incident cancer cases and 8.2 mil-
lion deaths were estimated to occur worldwide. Rising
prevalence over the past decades lends evidence to can-
cer as a serious global public health issue [1]. Based on
the most recent GLOBOCAN report on worldwide can-
cer incidence and mortality, projections estimate an in-
crease to 19.3 million incident cancer cases annually by
2025 [2]. Of this substantial global disease burden, over
half of incident cancer cases and deaths occur in less de-
veloped regions and these figures are similarly projected
to increase in the next decade [2].
The burden of cancer in Africa is particularly detri-
mental due to exposure to major risk factors, limited
awareness of early symptoms, and limited diagnostic fa-
cilities and access to care necessary to detect and treat
cancer patients [1, 3]. In Africa, 80% of cancers are first
diagnosed at advanced stages due, in part, to lack of ad-
equate screening and early detection [4]. Cancers associ-
ated with infectious agents are among the most
commonly diagnosed cancers in Africa [3]. Specifically,
HIV/AIDS infection and associated immunosuppression
has been shown to increase risk for AIDS-defining can-
cers (ADCs), including Kaposi sarcoma, non-Hodgkin
lymphoma, and invasive cervical cancer [5, 6]. ADCs are
cancers occurring in HIV-positive individuals, at which
point a patient is diagnosed with stage 3 HIV indicating
progression to AIDS [7, 8].
As Sub-Saharan Africa accounts for 71% of the 24.7
million global HIV/AIDS cases, infection-associated dis-
eases like cancer are of increasing concern [9]. Compar-
able with the 4.7% adult HIV prevalence in all of Sub-
Saharan Africa, Tanzania had a 5% HIV prevalence in in-
dividuals aged 15–49 and 1.4 million people living with
HIV in 2013 [9, 10]. Compared with neighboring Kenya
(6% adult prevalence) and Zambia (12.5% adult preva-
lence), Tanzania has seen success in infection control ef-
forts. In the last decade, Tanzania has improved HIV
management efforts by increasing access to antiretroviral
therapy (ART), with programs implemented nationally
in 2004 [9–12]. The number of people living with HIV
in Tanzania has declined from 7% in 2003/4 to 5.1% in
2011/12 [9].
As a result of scaling up HIV prevention services and
antiretroviral therapy (ART) coverage, studies reveal sus-
tained viral suppression and decreasing burden of ADCs
while predicting subsequent increasing burden of non-
AIDS-defining cancers (NADCs) in individuals receiving
ART [11, 13, 14]. HIV patients treated with ART are
found to be at increased risk for non-AIDS health com-
plications, many of which are also associated with in-
creasing age [13]. Recent data suggests increased
incidence of liver disease, cardiovascular disease, and
cancer in HIV-infected and treated patients compared to
age-matched non-HIV infected individuals, further sug-
gesting an association between HIV and cancer [13].
Mechanisms for the association between HIV infection
and NADC diagnoses include persistently elevated in-
flammation during long-term ART treatment [13, 15],
low CD4 counts in those on treatment [13, 16], and in-
creased longevity and age [11]. Analysis of aggregate
AIDS and cancer registry data in US adults suggests sta-
tistically significant excesses in ADCs (KS, NHL, invasive
cervical cancer) as well as NADCs potentially influenced
by immunosuppression [17]. HIV treatment is reducing
direct HIV and AIDS related morbidity and mortality in
Tanzania, and research is needed to detect how treat-
ment is changing the profile of diseases resulting from
sustained ART such as non-AIDS-defining cancers.
As Tanzania does not currently have a population-
based cancer registry, this study was conducted to gain
further understanding of Tanzania’s changing cancer
burden. This project, undertaken at the ORCI, the main
cancer treatment center of Tanzania in Dar es Salaam,
built upon our previous work on ano-rectal, squamous
cell carcinoma of the eye, and Hodgkin lymphoma
NADCs [11]. The first objective of this study was to esti-
mate the temporal pattern for additional types of
NADCs (lung, liver, and head and neck) between 2002
and 2014. This time period captured trends in NADCs
both before and after ART implementation. Secondly,
this study examined proportions of HIV-positive patients
diagnosed with NADCs from 2010 to 2014 in order to
investigate potential connection between prevalence of
HIV-related immunodeficiency and diagnosis of lung,
liver, and head and neck NADCs.
Methods
This retrospective study focused on lung, liver, and head
and neck NADCs and was conducted at the Ocean Road
Cancer Institute (ORCI) in Dar es Salaam, Tanzania. As
the main center for cancer treatment in the country,
ORCI receives patients from all geographical regions of
Tanzania. An electronic registry at ORCI is still being
developed and this study utilized ORCI’s hospital-based
cancer registry records [18]. Previous reports on this
population characterized ano-rectal, squamous cell car-
cinoma of the eye, and Hodgkin lymphoma NADC pa-
tients [11]. This study subsequently focused on lung,
liver, and head and neck NADCs.
Annual logbooks from 2002 to 2014 were reviewed for
total number of lung, liver, and head and neck NADC
cases diagnosed at ORCI. Data was not collected from
2007, as logbook records from this year were not avail-
able. Total numbers of lung, liver, and head and neck
cancers as well as all cancers diagnosed per year were
collected to calculate annual proportions of each of the
3 NADC types identified during this 12-year period.
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Corresponding to annual logbooks, medical records of
1127 patients with lung, liver, head and neck cancers di-
agnosed from 2010 to 2014 were identified and ab-
stracted. This shorter 5-year retrospective period was
chosen to characterize recent NADC trends and patient
characteristics in relation to HIV. Variables abstracted
from ORCI medical records included sex, age, region of
residence, tobacco and alcohol use, history of comorbidi-
ties, HIV status, cancer type, cancer stage, date of cancer
diagnosis, cancer treatment, cancer recurrence, subse-
quent cancer diagnoses, and recorded death/mortality.
Within medical records, pathology reports were utilized
to abstract the site and stage of cancer while radiology
and chemotherapy department documents provided in-
formation on clinical diagnosis and treatment modality.
Lung cancer diagnosis included patients with both
small cell and non-small cell cancer, as pathological
diagnoses and did not consistently distinguish between
types. Liver cancer diagnoses included patients with a re-
corded diagnosis of either “hepatocellular carcinoma” or
“hepatoma.” Head and neck cancers included cancer
sites in the following sites: oropharynx, parotid, tongue,
oral cavity, palate, lip, salivary gland, gingiva, intra-oral
jaw/mandible/maxilla, tonsil, maxillary sinus, sinonasal,
nasal, nasopharynx, larynx, hypopharynx, supra-/epi-
glottis, pharynx, neck (non-skin), and sub-mandible and
excluded malignancies of the skin, lymph nodes and
brain. In this study, head and neck cancers were grouped
into sub-categories of “oral cavity/oropharynx,” “nasal
cavity/paranasal sinuses,” and “hypopharynx/larynx/tra-
chea” for comparison according to anatomical grouping
of head and neck malignancies, described in the World
Health Organization International Agency for Research
on Cancer (IARC) Classification of Tumors [19].
Patients with the diagnosis of lung, liver, and head and
neck cancers identified from the logbooks but not con-
firmed by medical record pathology reports were not in-
cluded in this study. For individuals lacking site-specific
diagnoses in logbooks, medical records were retrieved,
reviewed, and patients were included or excluded based
on pathology report criteria. Geographic locations of resi-
dence reported in ORCI documents were classified on a
regional level to protect patient anonymity for those rare
cancers. Discrepancies between demographics reported by
logbooks and medical records were resolved by prioritiz-
ing data that was listed on the majority of medical record
reports. Numbers of recorded tobacco and alcohol users
at the time of cancer diagnosis were minimal in this popu-
lation, as displayed in Table 1, and were combined with
individuals with a history of substance use for the com-
parison of “ever use” to “never use” of tobacco and alcohol
between the NADC patient populations.
Due to missing HIV status data in several medical re-
cords, a separate ORCI-based HIV care and treatment
clinic (CTC) database was identified to supplement pa-
tient HIV status. This database is supported by the
Tanzanian Ministry of Health and housed at ORCI.
Linkage between patients contained in the NADC data-
set and the HIV database was performed on-site by
ORCI staff. This database provided additional HIV-
positive data on 20 patients, 17 with previously missing
data, 1 recorded as HIV-negative, and 2 previously re-
corded as HIV-positive.
Statistical analysis
Trends in absolute numbers and proportions of NADCs
compared to all cancers diagnosed at ORCI between
2002 and 2014 as well as 2010–2014 were analyzed
using Joinpoint Regression Program, Version 4.2.0 -
April 2015 [20, 21]. Categorical variables were examined
using Chi square or Fisher’s exact tests and continuous
variables were examined using t-test or Wilcoxon rank-
sum test according to the normality of the data. Multi-
nomial logistic regression models were used to model
multiple nominal HIV status outcome variables for cal-
culation of odds ratios and 95% confidence intervals to
determine associations between patient HIV-status and
covariates [22]. Data analysis was performed using SAS
6.4. The study was approved by the IRB committees of
the University of Michigan and the Ocean Road Cancer
Institute.
Results
A total of 2067 patients with lung, liver, and head and
neck cancers were recorded in the annual logbooks be-
tween 2002 and 2014 at the ORCI. Site specific numbers
included 165 lung, 389 liver, and 1513 head and neck
cancer patients presenting to ORCI according to hospital
logbook records. Between 2002 and 2014, the absolute
number of lung, liver, and head and neck NADCs diag-
nosed at ORCI increased by 33.8% (Joinpoint logarith-
mic annual percent change (APC) = 2.18% (Fig. 1). Site-
specific increases were observed in the number of lung
(APC = 7.67%), liver (APC 2002–2004 = 55.25%, APC
2004–2014 = 0.96%), and head and neck cancers (APC =
1.09%). The relative proportion of lung, liver, and head
and neck NADCs compared to all cancers diagnosed at
ORCI was 6.8% in 2002, exhibited a peak of 8.0% in
2003, and fell again to 5.6% in 2014 (2002–2014 APC
= -2.74%) (Fig. 1). Relative proportions of lung and liver
cancers increased (APC = 2.54%; 2002–2004 APC =
35.48%, 2004-2014 APC = -3.06% respectively), while the
proportion of head and neck cancers significantly de-
creased compared to all cancers diagnosed at ORCI from
2002-2014 (APC = -3.78%).
Among the subset of pathologically confirmed cases
from 2010 to 2014, for which we also abstracted infor-
mation on HIV status, a total of 1127 patients were
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diagnosed with lung, liver, and head and neck cancers.
We excluded five cases from our analyses, three who
were less than 18 years of age and two who were preg-
nant at the time of diagnosis. When focusing only on
this 5-year period, the absolute number of total NADC
cases increased by 5.7% from 2010 to 2014 (APC =
4.23%). Specifically, numbers of pathologically confirmed
lung (APC = 12.47%), liver (APC = 4.01%) and head and
neck (APC = 3.34%) cancer cases all increased from 2010
to 2014. The relative proportion of pathologically con-
firmed NADCs compared to all cancer diagnoses in-
creased from 5.8% in 2010 to 6.0% in 2014 (APC =
2.92%). Proportions of pathologically-confirmed lung
(APC = 11.07%), liver (APC = 2.80%), and head and neck
(APC = 2.07%) cancers each increased compared to total
cancer diagnoses between 2010 and 2014.
HIV status was available for 270 (24%) of the 1127
NADC cases diagnosed during this 5-year period. The
proportion of NADC patients that were recorded as
HIV-positive decreased slightly from 8.1% in 2010 to
7.1% in 2014 (APC = -3.77%). Medical record abstraction
alone identified 256 patients as having known HIV sta-
tuses (n = 63 HIV-positive; n = 193 HIV-negative) and
833 patients as having unknown HIV statuses. ORCI
Table 1 Total NADC (lung, liver, and head and neck) patient characteristics, 2010-2014a
All NADCs
(N = 1127)
N (%)
Lung
(N = 101)
N (%)
Liver
(N = 151)
N (%)
Oral cavity/
Oropharynxb
(N = 421)
N (%)
Nasal cavity/paranasal
sinusesc
(N = 230)
N (%)
Hypopharynx/larynx/
trachead
(N = 224)
N (%)
Female 410 (36.4%) 51 (50.5%) 63 (41.7%) 159 (37.8%) 98 (42.6%) 39 (17.4%)
Mean Age ± SD 54.3 ± 15.8 58.6 ± 13.8 47.1 ± 15.6 56.6 ± 15.2 47.9 ± 16.6 59.3 ± 13.4
Residence in Dar es Salaam 448 (39.8%) 53 (52.5%) 70 (46.4%) 140 (33.3%) 91 (39.6%) 95 (42.4%)
Smoking Status
Previous 404 (35.9%) 33 (32.7%) 27 (17.9%) 170 (40.4%) 52 (22.6%) 122 (54.5%)
Current 25 (2.2%) 2 (2.0%) 2 (1.3%) 12 (2.9%) 1 (0.4%) 8 (3.6%)
Never 477 (42.3%) 39 (38.6%) 71 (47.0%) 169 (40.1%) 125 (54.4%) 73 (32.6%)
Alcohol use
Previous 411 (36.5%) 30 (29.7%) 39 (25.8%) 182 (43.2%) 52 (22.6%) 108 (48.2%)
Current 54 (4.8%) 5 (5.0%) 5 (3.3%) 19 (4.5%) 11 (4.8%) 14 (6.3%)
Never 399 (35.4%) 31 (30.7%) 59 (39.1%) 143 (34.0%) 107 (46.5%) 59 (26.3%)
Tuberculosis 94 (8.3%) 26 (25.7%) 4 (8.0%) 32 (22.4%) 17 (22.4%) 15 (19.7%)
Co-morbiditiesf
Mean count ± SD 0.46 ± 0.76 0.97 ± 0.98 0.77 + 0.93 0.37 ± 0.65 0.34 ± 0.67 0.34 ± 0.63
HIV-status
Positive 81 (7.2%) 4 (4.0%) 11 (7.3%) 36 (8.6%) 22 (9.6%) 8 (3.6%)
Negative 189 (16.8%) 26 (25.7%) 24 (16.0%) 87 (20.7%) 38 (16.5%) 14 (6.3%)
Unknown 857 (76.0%) 71 (70.3%) 116 (76.8%) 298 (70.8%) 170 (73.9%) 202 (90.2%)
Advanced cancer stagee 655 (58.1%) 42 (41.6%) 49 (32.5%) 291 (98.0%) 135 (95.1%) 138 (85.7%)
Cancer Treatment Modality
Radiotherapy 770 (68.3%) 32 (31.7%) 40 (29.0%) 332 (81.6%) 174 (80.9%) 192 (88.1%)
Chemotherapy 574 (50.9%) 60 (59.4%) 87 (63.0%) 184 (45.3%) 128 (59.8%) 115 (52.5%)
Both 414 (38.6%) 15 (14.9%) 25 (18.1%) 158 (38.7%) 112 (52.1%) 104 (47.3%)
Recurrence 41 (3.6%) 0 0 20 (4.8%) 18 (7.8%) 3 (1.3%)
Subsequent cancer diagnosis (at least one) 159 (14.1%) 34 (33.7%) 30 (19.9%) 37 (8.8%) 39 (17.0%) 19 (8.5%)
Recorded Death 149 (13.2%) 14 (13.9%) 33 (21.9%) 51 (12.1%) 27 (11.7%) 24 (10.7%)
aTotals vary due to missing data
bOral cavity/oropharynx cancers include oropharynx, parotid, tongue, oral cavity, soft/hard palate, lip, salivary gland, gingiva, intra-oral mandible, and tonsil according to
WHO/IARC tumor classification
cNasal cavity/paranasal sinuses cancers include maxilla, maxillary sinus, sinonasal, nasal, and nasopharynx according to WHO/IARC tumor classification
dHypopharynx/larynx/trachea cancers include larynx, Hypopharynx, glottis, vallecula, pharynx, neck (non-skin), and submandibular according to WHO/IARC
tumor classification
eDefined as stages 3–4 and metastatic malignancies, % represents reported pathology department diagnosis
fComorbidities include Comorbidities include malaria, pleural effusion, pneumonia, ascites, syphilis, liver cysts, oral thrush, oral ulcers, sinusitis, yellow fever, etc
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records provided 93.1% of known HIV statuses and 6.9%
was identified through a separate HIV CTC clinic data-
base. Linkage with this separate HIV database increased
the number of patients with known HIV statuses to 270
(n = 81 HIV-positive; n = 189 HIV-negative) resulting in
an HIV-positive status correction factor of 6.2% in
NADC patients diagnosed between 2010 and 2014.
Table 1 shows demographic characteristics, HIV, and
health status of lung, liver, and head and neck cancer
patients. The distribution of gender between lung and
liver cancers was 50.5 and 41.7% female, for the 2 can-
cers respectively. Nearly twice the percent of males
were diagnosed with head and neck cancers compared
to females (33.8% female, 66.2% male). Of all NADC
cases, 11.7% of females were recorded to be HIV-
positive, while only 4.6% of all males were recorded as
HIV-positive, representing a female to male ratio of 2.5
in this NADC population.
Patients with cancer of the hypopharynx, larynx, and
trachea regions of the head and neck had the oldest
mean age at diagnosis (59.3 ± 13.4 years), while liver can-
cer patients had the youngest mean age at diagnosis
(47.1 ± 15.6 years). Head and neck cancers, specifically
those of the oral cavity and oropharynx as well as of the
hypopharynx, larynx and trachea regions, had the most
patients who had previously smoked (40.4% and 54.5%
respectively) and previously consumed alcohol (43.2%
and 48.2% respectively), while the majority of patients
diagnosed with all other NADCs in this study indicated
never smoking or drinking alcohol. The highest percent-
ages of patients with recorded hepatitis B, hepatitis C,
and cirrhosis diagnoses were in liver cancer patients
(53.5%, 9.8%, and 71.1% respectively). Lung cancer pa-
tients had the greatest percentage of tuberculosis diag-
noses (25.7%), the largest mean number of comorbidities
(0.97 ± 0.98), and the largest percentage of patients with
Fig. 1 Numbera and proportionb of lung, liver, and head and neck NADCs, 2002–2014. a Total number of lung, liver, and head and neck cancers
diagnosed annually at ORCI according to logbooks. b Proportion of total lung, liver, and head and neck cancers diagnosed compared to all
cancers diagnosed annually at ORCI according to logbooks
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at least one subsequent cancer diagnosis (33.7%) com-
pared to liver and head and neck cancer patients. The
largest proportion of recurrence was recorded in 4.7% of
all head and neck cancers, and specifically 7.8% of pa-
tients diagnosed with cancer of the nasal cavity or para-
nasal sinuses, while no recorded cases of recurrence
were found in lung or liver cancer patients. The largest
proportion of recorded deaths, 21.9%, occurred in indi-
viduals diagnosed with liver cancer compared to patients
with lung cancer and all as well as sub-categories of
head and neck cancers.
Of NADC patients, 4.0% of lung, 7.3% of liver, and
7.5% of all head and neck cancer cases were HIV-
positive. Of patients known to be HIV-positive, 4.9%
were diagnosed with lung cancer, 13.6% had liver cancer,
and 81.5% were diagnosed with a head and neck cancer.
Specifically, 44.4% of HIV-positive patients were diag-
nosed with cancer of the oral cavity/oropharynx, 27.2%
had cancer of the nasal cavity/paranasal sinuses, and
9.9% had cancer of the hypopharynx/larynx/trachea (see
footnotes of Table 1). When stratified by year, a nearly
25% increase in HIV-positive NADC cases occurred be-
tween 2012 and 2013, with HIV-positive head and neck
NADC patients representing the majority of this in-
crease. During the 5-year period from 2010 to 2014,
HIV-positive NADC patients were diagnosed at a youn-
ger average age, decreasing from 49.8 years in 2010 to
44.1 years of age in 2014.
Table 2 shows NADC patient characteristics and com-
pares differences in these variables according to HIV-
status, either –positive, -negative, or unknown. P-values
and odds ratios represent the comparison of HIV-
positive patients and individuals with an unknown HIV
status to those recorded to be HIV-negative. Compared
to HIV-negative NADC patients, both HIV-positive and
HIV- unknown patients were more likely to be female,
with HIV-positive patients having more than twice the
odds of HIV-negative patients (OR = 2.78; 95% CI 1.63,
4.74). Both HIV-positive and HIV-unknown individuals
were more likely to reside in Dar es Salaam, have under-
gone treatment with radiotherapy, and have reported
ever using alcohol compared to HIV-negative individ-
uals, while HIV-positive patients were significantly less
likely than HIV-negative patients to have reported ever
smoking. Both HIV-positive and –unknown NADC pa-
tients were likely to have been diagnosed with fewer co-
morbidities, and were less likely to experience malignant
recurrence compared to HIV-negative patients (OR =
0.54; 95% CI 0.29, 1.00). HIV-positive patients were sig-
nificantly more likely to have been diagnosed with tuber-
culosis (OR = 2.31; 95% CI 1.05, 2.12) and were more
likely to have recorded mortality while HIV-unknown
patients were less likely to exhibit these characteristics
compared to HIV-negative patients. Individuals having
an unknown HIV status were significantly less likely to
be diagnosed with an advanced stage malignancy (OR =
0.26; 95% CI 0.06, 1.08) as well as a subsequent cancer
diagnosis (OR = 0.64; 95% CI 0.42, 0.97) and less likely
to have undergone chemotherapy when compared to
HIV-negative NADC patients.
Discussion
This study characterized the burden and proportional
changes in distributions of lung, liver, and head and neck
NADCs prior to and following ART introduction in
Tanzania and revealed multiple notable findings. First,
the number of lung, liver, and head and neck cancer
diagnoses at ORCI increased by 33.8% from 2002-2014.
Second, compared to all cancers diagnosed at ORCI
from 2010-2014, we observed that proportions of lung
and liver cancers increased, while the proportion of head
and neck cancers significantly decreased compared to all
cancers. Third, the number of pathologically confirmed
lung, liver, and head and neck cancers increased from
2010-2014, although we observed a slight decrease in
the proportion that were HIV-positive. Fourth, the lar-
gest proportion of HIV-positive cases were patients diag-
nosed with cancers of the head and neck. Lastly, over
half the patients diagnosed with these NADCs during
2010-2014 presented to ORCI at advanced stages of
malignancy.
Increasing numbers of lung, liver, head and neck can-
cers were observed from 2002-2014, following national
ART implementation in 2004, but a proportional de-
crease was observed compared to all cancers diagnosed
at ORCI. These findings should be placed within the
context of a 45.8% increase of total cancers diagnosed at
ORCI and a 30% increase in the Tanzanian population
during the same time period [23]. Cervical, prostate,
breast, Kaposi sarcoma, and esophageal cancers are
among the most common types of malignancies in
Tanzania [24]. While cervical, prostate, and breast can-
cers account for large proportions of the cancer burden
in this population, the proportion of Kaposi sarcoma, an
AIDS-defining malignancy, to all other cancers diag-
nosed is decreasing [24, 25]. Although NADCs evaluated
in this study decreased in percentage over the 12-year
period, ongoing evolution of risk factors and population
characteristics in Tanzania may lead to increasing pro-
portions of these types of malignancies in the future.
The increasing relative proportion of all pathologically
confirmed lung, liver, and head and neck NADCs (APC
= 2.92%) between 2010 and 2014 compares to higher
relative increasing proportions of ano-rectal cancer,
squamous cell carcinoma of the eye, and Hodgkin
lymphoma NADC diagnoses among all cancers at ORCI
from 2002-2012 reported in our recent study (APC =
4.68%) [11]. Potential reasons for noting a smaller
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magnitude of increase in this study include the smaller
5-year period of analysis, the short survival of lung and
liver cancers that may have limited the inclusion of those
cases from the ORCI site, limited sensitivity of some
diagnostic tools [26–28], and lacking diagnostic imaging
tools that are becoming more prevalent in developing
countries for diagnosis of lung and liver cancers [29].
Similarly, head and neck cancers, especially those of the
oral cavity, are diagnosed upon presentation of advanced
visible symptoms rather than through early detection
[30]. Larger numbers of head and neck cancers diag-
nosed in 2010 may represent accumulated undiagnosed
burden while more current numbers may reflect annual
rates, contributing to this observed proportional de-
crease compared to all ORCI cancer diagnosis. Further,
risk factors contributing to head and neck cancer eti-
ology such as tobacco and alcohol use, HPV, and other
infections were largely unrecorded in the ORCI medical
records and may influence the proportional decrease in
cases noted when head and neck cancers were compared
to all cancer diagnoses from 2010-2014 [31]. Ano-rectal
cancer, squamous cell carcinoma of the eye, and Hodg-
kin lymphoma, as NADCs, are diagnosed earlier in
pathogenesis, which makes underreporting of these can-
cers unlikely compared to the 3 groups of cancers exam-
ined in this study [32–34].
Comparison between NADC patient HIV status
groups revealed expected differences between HIV-
positive and -negative individuals, but also exhibited dif-
ferences between the group of patients with unknown
HIV status from those who were HIV-negative. This
unknown-status group accounted for a large proportion
of the sample and differed from the other 2 groups
based on multiple factors. Significantly different charac-
teristics of HIV-unknown versus HIV-negative patients
include that HIV-unknown patients were likely to be
older, less likely to be diagnosed at an advanced stage of
malignancy, and less likely to have been diagnosed with
a subsequent type of cancer after their initial diagnosis.
Additionally, HIV-unknown NADC patients had fewer
comorbidities, were less likely to have tuberculosis, and
less likely to have recorded mortality suggesting that this
Table 2 Characteristics of lung, liver, and head and neck NADC patients by HIV status, 2010-2014a
HIV-negative
(N = 189)
N (%)
HIV-positive
(N = 81)
N (%)
P valueb
HIV-positive
vs. -negative
OR (95% CI)c
HIV-positive
vs. -negative
HIV-unknown
(N = 857)
N (%)
P valueb
HIV-unknown
vs.-negative
OR (95% CI)c
HIV-unknown
vs. -negative
Female 65 (34.4%) 48 (59.3%) 0.0001* 2.78 (1.63, 4.74) 297 (34.7%) 0.9449 1.01 (0.73, 1.41)
Mean Age ± SD 48.1 ± 15.6 47.6 ± 12.6 0.7878 1.00 (0.98, 1.02) 56.3 ± 15.7 <0.0001* 1.03 (1.02, 1.05)
Residence in Dar es Salaam 72 (38.1%) 41 (50.6%) 0.0560 1.67 (0.99, 2.82) 335 (39.1%) 0.7768 1.05 (0.76, 1.45)
Advanced cancer staged 115 (60.8%) 42 (51.9%) n/a n/a 498 (58.1%) 0.0447* 0.26 (0.06, 1.08)
Cancer Treatment Modality
Radiotherapy 111 (58.7%) 56 (69.1%) 0.1221 1.59 (0.88, 2.85) 603 (70.4%) 0.0023* 1.70 (1.21, 2.39)
Chemotherapy 97 (51.3%) 44 (54.3%) 0.6498 1.13 (0.70, 1.95) 433 (50.5%) 0.7092 0.94 (0.68, 1.30)
Tuberculosis 20 (10.6%) 19 (23.5%) 0.0364* 2.31 (1.05, 2.12) 55 (6.4%) 0.2532 0.71 (0.39, 1.28)
Co-morbiditiese
Mean count ± SD 0.59 ± 0.80 0.41 ± 0.75 0.0679 0.74 (0.52, 1.05) 0.44 ± 0.74 0.0720 0.80 (0.65, 0.95)
Smoking Status
Ever use 71 (37.6%) 19 (23.5%) 0.0492* 0.54 (0.29, 1.00) 339 (39.6%) 0.4543 1.14 (0.81, 1.62)
Never 84 (44.4%) 42 (51.9%) - - 351 (41.0%) - -
Alcohol use
Ever use 80 (42.3%) 29 (35.8%) 0.8749 1.07 (0.58, 2.00) 356 (41.5%) 0.6032 1.10 (0.77, 1.56)
Never 74 (39.2%) 25 (30.9%) - - 300 (35.0%) - -
Recurrence 9 (4.76%) 1 (1.2%) 0.2904 0.25 (0.03, 2.01) 31 (3.6%) 0.4577 0.75 (0.35, 1.60)
Subsequent cancer diagnoses 35 (18.5%) 15 (18.5%) 1.0000 1.00 (0.51, 1.95) 109 (12.7%) 0.0362* 0.64 (0.42, 0.97)
Recorded Death 28 (14.8%) 17 (21.0%) 0.2123 1.53 (0.78, 2.98) 104 (12.14%) 0.3153 0.79 (0.51, 1.25)
aMultinomial logistic regression comparing HIV-positive and HIV-unknown to HIV-negative patient group
bChi-squared tests/Fisher’s exact test for categorical variables; t-tests/Wilcoxin rank-sum tests for continuous variables
cOdds Ratios (95% Confidence Intervals) calculated using multinomial logistic regression models (Reference = HIV-negative)
dDefined as stages 3–4 and metastatic malignancies, % represents reported pathology department diagnosis
eComorbidities include malaria, pleural effusion, pneumonia, ascites, syphilis, liver cysts, oral thrush, oral ulcers, sinusitis, yellow fever, etc
*Significant at alpha <0.05
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patient population may be healthier than the HIV-
negative and -positive NADC patient groups. Overall
better health status in HIV-unknown NADC patients
compared to those testing HIV-negative, based on the
variables examined, may partially explain their lack of
documented HIV sero-status, as less health care service
utilization in the absence of other illnesses may contrib-
ute to less frequent referral to HIV testing. However,
other barriers to HIV testing may exist for these patients
and HIV-unknown patients cannot be assumed to be
HIV-negative. In fact, the HIV-unknown patient group
exhibited some similarities to the HIV-positive patient
group including containing more females and being
likely to have been treated with radiotherapy compared
to HIV-negative patients.
Although only about one quarter of NADC patient
HIV status was known, a female to male ratio of 2.5 was
observed for HIV-positivity. This relationship exceeds
the known ratio of HIV-positive females to males of 1.5
in the general Tanzanian population [35]. When NADC
patients were compared based on HIV-status, HIV-
positive individuals were more than twice as likely to be
females compared to HIV-negative individuals, which
adheres to, yet also exceeds, the disproportional national
burden of HIV infection in women [35]. The proportion
of HIV-positive patients diagnosed with lung, liver, and
head and neck cancers decreased from 8.1 in 2010 to
7.1% in 2014, with a logarithmic annual change of
-3.77%. This contrasts increasing proportions of HIV-
positive NADC patients found in our recent study
during 2002-2012 at ORCI (APC = 16.02%) as well as
findings from a study conducted in neighboring
Kampala, Uganda which revealed increasing incidence of
lung, liver, and nasopharyngeal cancer in HIV-infected
individuals between 1988-2002 [11, 36]. While decreas-
ing prevalence of HIV-positivity was noted in this pa-
tient population over time, prevalence remained above
6% throughout 2010-2014 which consistently exceeds
the 2013 national prevalence of 5% in Tanzania [9, 10].
Elevated prevalence of HIV-positivity within this NADC
population may suggest HIV-related immunodeficiency
as a contributing risk factor for developing NADCs,
though more complete data will be necessary to confirm
this association. The observed decrease in HIV-positive
NADC patients in this study may be due to a large pro-
portion of patients having an unknown HIV status. Miss-
ing HIV status data in ORCI files may be due to
patients’ unwillingness to disclose their status to ORCI
clinicians, incomplete record transfer from referring
medical facilities, or patients not being recommended
for or failing to complete testing. The slight reduction in
HIV-positive NADC cases may further be influenced by
improved longevity and decreased potential for HIV
transmission of those managing infection with ART.
Head and neck cancer cases accounted for the largest
proportion of HIV-positivity in this study. HPV infec-
tion, especially by HPV-16, has been commonly identi-
fied as a risk factor contributing to the onset of head
and neck cancers, predominantly those of the orophar-
ynx, tonsils, and the base of the tongue [31]. A recent
cohort study found that the relative risk of carrying HPV
decreased proportionately by 11% for each 100 CD4
cells/μL increase, suggesting plausible co-infection of
HPV in immunosuppressed including HIV-positive indi-
viduals, as well as attenuating risk of HPV infection with
improved immune function [37]. The large number of
HIV-positive head and neck cancer cases in this study
may be due to this co-infection, though more complete
HPV status data in ORCI medical records will be neces-
sary to confirm this association.
Over half of the lung, liver, and head and neck NADC
patients diagnosed between 2010-2014 were identified as
having stage III, IV, or metastatic malignancies. When
separated by HIV status, no HIV-positive NADC pa-
tients had less than an advanced stage of cancer (stages
III-IV or metastatic malignancy) while only two HIV-
negative patients had malignancies diagnosed at a stage
earlier than stage III. The ORCI and cancer care facilities
at Bugundo Medical Centre in Tanzania are estimated to
have the capacity to only serve about 5000 of the esti-
mated 35,000 new cancer cases in Tanzania each year
[24]. Limited cancer treatment resources and geograph-
ical barriers to seeking care delays presentation for dis-
ease management and contributes to the 80% mortality
in Tanzanian cancer patients each year [24]. The major-
ity of advanced stage NADCs received by ORCI reveals
how late in pathogenesis patients present for treatment
and the lack of early-stage cancers contained in the
ORCI hospital-based cancer registry. Due to the urgency
of initiating treatment in these cases, ORCI medical
records do not always contain patient history details
such as past and current comorbidities or substance use.
The tendency for this data to be contained in medical
records from referring hospitals and clinics identifies
these entities as the chief source of data on patients’
lifetime health.
In this study, the distribution of gender between lung
and liver NADCs was nearly equal which is consistent
with population data reported by East African Countries
in Cancer Incidence in Five Continents [38]. Nearly twice
the number of males were diagnosed with head and neck
cancers compared to females, consistent with the male
to female ratio of 2:1 previously found in head and neck
cancer cases at Muhimbili National Hospital, Tanzania
from 2012-2013 [39]. This study also observed the great-
est percentage of tuberculosis diagnoses in lung cancer
patients and hepatitis B, hepatitis C, and cirrhosis diag-
noses in liver cancer patients. These findings within
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Tanzanian NADC population are consistent with previ-
ously documented risk factors contributing to lung and
liver cancers [40, 41].
In contrast to the reported increasing average age of
HIV-positive patients with ano-rectal cancer, squamous
cell carcinoma of the eye, and Hodgkin lymphoma from
2002-2012 [11], we observed a decreasing average age in
HIV-positive lung, liver, and head and neck NADC pa-
tients from 2010-2014. This difference may be due to the
types of cancers that HIV-positive individuals were diag-
nosed with in this study compared to those included in
our previous publication [11] and associated average ages
of onset of these malignancies. In this study, HIV-positive
patients diagnosed with cancer in 2010 were individuals
having lung and head and neck cancers; no liver cancer
cases were recorded as HIV-positive during this year.
HIV-positive patients diagnosed with cancer in 2014 had
liver and head and neck cancers; no lung cancer cases
were recorded as HIV-positive during this year. Lung can-
cer usually occurs in those with more advanced age
(≥65 years), while liver cancer tends to occur at a younger
age (mean 34.7 years) in southern Africa, which may par-
tially explain the observed decrease in HIV-positive pa-
tients’ average age during these 5 years [42, 43].
Epidemiologic research focused on non-AIDS-defining
cancers in Tanzania is limited. This study of NADCs in
patients presenting to ORCI has multiple strengths. This
study builds upon work previously done in this popula-
tion to analyze changing patterns of Kaposi’s sarcoma as
well as work on three other NADCs in order to more
broadly characterize changing cancer burden in
Tanzania and contribute to knowledge for future re-
search in this population [11, 25]. This large dataset of
patients with lung, liver, and head and neck cancers con-
tains cases that were pathologically confirmed and in-
cluded individuals from a majority of Tanzania’s
geographic regions. In the absence of a population-based
cancer registry, the consistency of patient demographics
by cancer site with those reported by Cancer Incidence
in Five Continents suggests general comprehensiveness
of the ORCI hospital-based cancer registry.
Consistent with methodology detailed in our previous
study [11], this study was a secondary retrospective ana-
lysis of ORCI medical record data, for which abstraction
was limited to the completeness of logbooks and patient
files. As logbooks contained medical record numbers as-
sociated with cancer diagnoses, identification of medical
records corresponding to these malignancies of interest
was dependent on the quality of documentation by
ORCI staff. Limitations related to abstraction of medical
record data included patient history and appointment
notes taken by multiple clinicians in differing formats
and levels of detail. Due to the lack of routine HIV-
screening at ORCI, many patients had missing HIV-
statuses even when files indicated that patients had been
tested. For this reason, additional HIV CTC clinic data
was utilized and linked to this dataset. After HIV data-
base linkage, 24.0% of lung, liver, and head and neck
NADC patients had a known HIV-status which com-
pares to the 30.0% of ano-rectal, squamous cell carcin-
oma of the eye, and Hodgkin lymphoma NADC patients
with a supplemented HIV-status found in the previous
NADC study at ORCI [11]. Due to the overall lack of
consistent HIV status data in ORCI medical records, the
slight decrease in HIV-positive NADC cases in this study
should be interpreted with caution. Screening for add-
itional cancer risk factors such as HPV is also not rou-
tinely completed at ORCI. Given the association between
HPV infection and onset of head and neck cancers,
more complete data would be informative in this context
[31]. Limited available data on HIV and HPV infection
in this hospital-based cancer population prevents a clear
understanding of the driving force behind incidence of
NADCs in Tanzania at this time.
Future research into NADCs in the Tanzanian popula-
tion should include linkage of ORCI patient data with
HIV CTC clinic data in order to verify and supplement
HIV statuses of cancer patients. Since CTC clinic files
are housed at ORCI, future studies should further utilize
these files to understand additional factors contributing
to NADC incidence such as HIV treatment details, CD4
count, co-infections, height and weight for BMI calcula-
tions, and more thorough substance use data. Over half
of the patients in this study presented at ORCI with ad-
vanced stages of malignancy. To better capture cancer
patients at earlier stages of disease, we recommend that
projects focus on collecting data at regional health facil-
ities, private health clinics, or other disease screening fa-
cilities (such as HIV or HPV) rather than collecting data
on patients whose diseases have progressed to the point
of presenting at ORCI for management. Earlier capture
of NADC cases at referring health facilities has the
potential to more completely inform patient histories
of infection and co-morbidities, including hepatitis
and cirrhosis, through routine blood panels. More
complete data on risk factors and comorbidities from
these health facilities will contribute to a better un-
derstanding of the etiology and pathogenesis that lead
to development of uncommon non-AIDS-defining
malignancies. Future studies should examine infec-
tious and other risk factors contributing to the grow-
ing prevalence of these NADCs and within the HIV-
positive population of Tanzania. With an increased
understanding of the role of infectious agents in
pathogenesis, intervention and management strategies
can more accurately target and address the docu-
mented increasing prevalence of non-AIDS-defining
malignancies in Tanzania.
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Conclusions
In conclusion, this study offers further evidence for in-
creasing trends in non-AIDS-defining cancer frequency
at the ORCI. Specifically, burden of lung, liver, and head
and neck cancers have increased between 2002-2014
which coincides with elevated trends in ano-rectal can-
cer, squamous cell carcinoma of the eye, and Hodgkin
lymphoma—three additional NADCs—recently reported
from 2002-2012 in this population [11]. As a wider pro-
file of NADC diagnoses is found to be increasing, evi-
dence of changing cancer burden following national
ART implementation grows stronger. Future research
must examine trends in AIDS-defining cancers through-
out this time period as well as the etiology of these and
other NADCs as a contributor to increasing numbers of
cancer diagnoses in Tanzania. Such research should
examine disease status and duration of cancer patients
infected by HIV, HPV, and hepatitis, as well as patient
health status at earlier stages of cancer diagnosis docu-
mented at regional, private, and screening facilities. Add-
itionally, this study further supports the necessary
development of a National AIDS Control Program
(NACP) database in Tanzania for the comprehensive
and centralized recording of HIV/AIDS diagnoses, infec-
tion duration, and treatment in order to gain a more
complete understanding of how HIV infection relates to
trends in NADC prevalence.
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